Objective: Heart failure affects more than 5 million U.S. adults, and approximately 20% of individuals with heart failure experience depressive symptoms. Depression is detrimental to prognosis in heart failure, conferring approximately a 2-fold increase in mortality risk. Medication nonadherence may help explain this relationship because depressed patients are less likely to adhere to the medication regimen. Method: Depression, electronically monitored medication adherence, and mortality were measured in a sample of 308 patients with heart failure participating in a study of self-management behavior. Cardiovascular and all-cause mortality data were obtained from the Centers for Disease Control and Prevention's National Death Index (median 2.9-year follow-up). Cox proportional hazards regression was used to assess the relationship between depression and mortality, with and without adjustment for age, gender, disease severity, and medication nonadherence. Results: In adjusted analyses, depression was associated with an increased all-cause mortality risk (hazard ratio 1.87; 95% confidence interval 1.04 -3.37). Depression was not related to cardiovascular mortality, potentially because of a low number of cardiac-related deaths. When medication nonadherence was added to the model, nonadherence (hazard ratio 1.01; 95% confidence interval 1.004 -1.02), but not depression, predicted all-cause mortality risk. Conclusions: Depressive symptoms confer increased all-cause mortality risk in heart failure, and medication nonadherence contributes to this relationship. Depression and nonadherence represent potentially modifiable risk factors for poor prognosis. Future research is needed to understand whether interventions that concomitantly target these factors can improve outcomes.
In the United States, 5.7 million persons Ն20 years of age have heart failure (HF) and 870,000 new HF cases are diagnosed annually (Mozaffarian et al, 2015) . The prevalence of HF will increase 46% by 2030, so that Ͼ8 million U.S. adults Ն18 years of age will have HF (Mozaffarian et al, 2015; Heidenreich et al., 2013) . Despite efforts to improve outcomes, mortality in HF remains high. The 1-year mortality rate for Medicare ben-an increased risk of mortality in HF (Sokoreli, de Vries, Pauws, & Steyerberg, 2016) .
Approximately one fifth of HF patients experience clinically significant symptoms of depression symptoms during the course of their illness (Rutledge, Reis, Linke, Greenberg, & Mills, 2006) . Freedland, Carney, Rich, and Caracciolo (1991) first reported a trend toward an increased length of hospitalization and 1-year mortality in depressed hospitalized HF patients. Although there was no difference in discharge vital sign status or 3-month readmission between patients with and without major depression, 50% of patients who met criteria for major depression at the time of index hospitalization died by the 1-year follow-up compared with 29% of nondepressed patients (Freedland, Carney, Rich, & Caracciolo, 1991) . Following the investigation of Freedland, Carney, Rich, and Caracciolo (1991) and additional studies, meta-analyses have confirmed the pattern of reduced survival in depressed HF patients (Rutledge, Reis, Linke, Greenberg, & Mills, 2006; Sokoreli, de Vries, Pauws, & Steyerberg, 2016) . Given the increased mortality risk conferred by comorbid depressive symptoms, greater understanding of factors that contribute to worse prognosis in depressed HF patients is needed to guide intervention efforts.
One potential mechanism of increased risk is poor disease selfmanagement. Depression has long been recognized as a barrier to treatment adherence. As such, depression may lead to increased mortality through its negative effects on self-management behaviors such as medication adherence. In the case of HF, managing medication regimens encompassing varied dosing, timing, and frequency can be difficult. Medication adherence estimates in HF range from approximately 40% to 60%, although at least 88% adherence may be necessary to achieve improved outcomes (Wu et al., 2009) . Proper medication adherence is critical for managing risk related to cardiac events and worsening cardiovascular disease (CVD), such as reducing high blood glucose levels and improving lipid profiles. Better adherence is associated with lower rates of emergency room visits, fewer cardiac events and readmissions, and shorter hospital stays (Esposito, Bagchi, Verdier, Bencio, & Kim, 2009; Gehi, Ali, Na, & Whooley, 2007) . Better medication adherence is also linked to reduced mortality risk in HF (Fitzgerald et al., 2011) .
Medication adherence appears to be more difficult for patients with comorbid depressive symptomology. Depression has been linked to nonadherence in CVD (Bane, Hughes, & McElnay, 2006) as well as patient-reported difficulty taking medications in HF (Morgan et al., 2006) . A cross-sectional analysis from the Heart and Soul study revealed that depressed patients with CVD were more likely to report skipping and incorrectly taking their medications than nondepressed patients, although no difference emerged in reports of forgetting to take medications (Gehi, Haas, Pipkin, & Whooley, 2005) . Thus, it is reasonable to expect that poor medication adherence would reduce treatment effectiveness and increase mortality risk in patients with comorbid HF and depression. Consistent with this reasoning, Wu, Lennie, Dekker, Biddle, and Moser (2013) reported that the combined depression and medication nonadherence were associated with 5 times greater risk of cardiac events during a 3.5-year follow-up in patients with HF (Wu et al., 2013) . Given these findings, it is important to determine whether medication nonadherence contributes to the relationship between depression and mortality in HF.
Method Participants
The present study is a secondary analysis from the Heart Adherence, Behavior, and Cognition study (trial identifier: NCT01461629), which was a longitudinal, observational study of the impact of psychosocial and cognitive factors on self-care behaviors in older adults with HF (Dolansky et al., 2016) . The Heart Adherence, Behavior, and Cognition study enrolled 372 older adults with HF, of which 308 had complete data for the variables of interest in this report. Participants were recruited from inpatient (n ϭ 50) and outpatient (n ϭ 322) cardiology services at two hospital systems in northeast Ohio. Individuals with documented systolic HF (i.e., HF diagnosis was verified within 36 months prior to study enrollment) were eligible for inclusion if they were aged 50 -85 years at enrollment and classified as NYHA class II or III by their physician. Individuals were ineligible if they had cardiac surgery within 3 months prior to enrollment, had a history of neurological disorder or injury (e.g., Alzheimer's disease, dementia, stroke, seizures), moderate or severe head injury, past or current significant psychiatric disorders (e.g., psychotic disorders, bipolar disorder, learning disorder, developmental disability), renal failure requiring dialysis, untreated sleep apnea, current substance abuse or within the past 5 years, or were currently using a home telehealth HF monitoring program.
Measures
Depressive symptoms. The Patient Health Questionnaire-9 (PHQ-9), a nine-item questionnaire, was used to assess depressive symptoms (Kroenke, Spitzer, & Williams, 2001 ). Scores range from 0 to 27, with higher scores representing greater depressive symptomology. Total scores are categorized as representing none to minimal (0 -4), mild (5-9), moderate (10 -14), moderately severe (15) (16) (17) (18) (19) , and severe depression (20 -27), (Kroenke et al., 2001) . A trained research assistant administered the PHQ-9 at the baseline and third study visits. The two scores were averaged to create a more reliable measure of each participant's level of depression. A score of Ն5 indicated the presence of clinically significant depression symptoms.
Medication nonadherence. Participants completed 28 days of medication monitoring using an electronic Medsignals pillbox (VitalSignals, LLC, Lexington, KY). The Medsignals pillbox transferred data to an electronic server through the participants' home telephone lines. The pillbox contained four individual bins so that up to four common HF medications (e.g., beta-blockers, angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, diuretics, aspirin, aldosterone antagonists, Plavix, and statins, selected in ascending order) were tracked. If necessary, such as in the event of a prescribed change in the medication regimen, adjustments were made in the pills selected for monitoring. Participants were instructed to take their medications as prescribed.
Medication nonadherence was defined as the percentage of days a participant did not follow their prescribed regimen. This was calculated as the number of days that the regimen was not followed (i.e., missed doses or overdoses) divided by the number of days monitored, expressed as a percentage). The percentage nonadherThis document is copyrighted by the American Psychological Association or one of its allied publishers.
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ence for each of the monitored medications was averaged to create a total score with possible scores ranging from 0% to 100%. Days the pillbox was not used for a specific reason, such as travel or hospitalization, were excluded. Medication adherence was treated as a continuous variable in analysis. The first 7 days of monitoring occurred between the second and third study visits and was considered to be a behavioral run-in to allow the participants the opportunity to learn to use the pillbox and incorporate the pillbox into their routine. Only the final 21 days of monitoring were included in analyses.
Covariates. Demographic and medical covariates assessed included age, gender, and disease severity. Age and gender were determined through self-report questionnaires. HF severity was assessed using physician-documented NYHA class. A trained research assistant assessed self-reported HF symptoms and limitations at baseline to confirm NYHA classification at the time of study participation.
Mortality. All-cause and cardiovascular mortality were determined using data obtained from the Centers for Disease Control and Prevention's National Death Index (http://www.cdc.gov/nchs/ ndi.htm). Deaths recorded through December 2014 were obtained, which provided a median 2.9-year follow-up. Cardiovascular deaths were defined by the following International Classification of Diseases, 10th revision, codes: acute rheumatic fever/chronic rheumatic heart diseases (I00-I09), hypertensive heart disease (I11), hypertensive heart and renal disease (I13), coronary heart disease (I20-I25), other heart diseases (I26-I51), essential hypertension and hypertensive renal disease (I10, I12, I15), or cerebrovascular diseases (I60-I69), (World Health Organization, 2004) .
Procedure
The study protocol was approved by the institutional review boards of Kent State University, Summa Health System, and University Hospitals of Cleveland. Participants were recruited from August 2010 through October 2013. Trained research assistants conducted medical chart review of patients admitted under the inpatient cardiology service or scheduled for an outpatient cardiology visit to determine whether individuals potentially met eligibility criteria based on screening of relevant factors (e.g., chart diagnosis of systolic HF with ejection fraction Ͻ40% for at least 3 months and verifiable in the medical record within 3 years of study enrollment). Following written informed consent, participants completed four study visits over the course of 1-2 months as well as 28 days of medication monitoring. At the baseline visit, demographic, psychosocial, and medical history was collected using self-report questionnaires and interviews. Approximately 2 weeks later, a research assistant conducted the second visit at the participant's home. This visit included installation of the pillbox. The third visit occurred approximately 1 week later and included a check of the electronic pillbox. The final visit, which included collection of the pillbox, occurred 3 weeks later.
Analytic Plan
Missing data. Of the enrolled sample, 332 individuals completed the four study visits and 309 had complete medication adherence data. Equipment failure and refusal and/or inability to use the pillbox were the most common reasons for missing medication monitoring data. Of those with complete medication adherence data (n ϭ 309), one individual was missing PHQ-9 data. We used listwise deletion of individuals missing data on variables included in multivariable analyses (i.e., age, gender, PHQ-9 scores), yielding a final sample of 308.
Preliminary analyses. Means, standard deviations, frequencies, and percentages were used to summarize sample characteristics. Pearson 2 tests and t tests were used to examine differences between depressed and nondepressed participants.
Prior to testing hypotheses, data were examined for violations of the assumptions of regression and Cox proportional hazards modeling. To examine potential violations of univariate normality, skewness and kurtosis statistics were calculated. Bivariate correlations were examined to assess for the presence of multicollinearity. The Schonfield residuals were used to test the proportionality of hazards assumption for continuous data. Examination of plots was used to test the assumption for categorical variables. No violations of assumptions were evident. The criterion for statistical significance was set at p Ͻ .05 for correlation and linear regression analyses. For Cox proportional hazards ratios, 95% confidence intervals (CIs) were used. In addition, a reduction of Ն3% in the age-adjusted log hazard ratio (HR) for depression following adjustment for a potential mediator was deemed to indicate significant mediation.
Primary and secondary analyses. Hierarchical linear regression was used to test the relationship between PHQ-9 scores and medication nonadherence. In Block 1, covariates (i.e., age, gender, and disease severity) were entered. In Block 2, categorical PHQ-9 scores were added to the model. Medication nonadherence was the dependent variable. Cox proportional hazards regression (Cox, 1972; Cox & Oakes, 1984) was then used to assess the relationship between depressive symptoms and mortality, with and without adjustment confounding variables. For both outcomes (i.e., allcause and cardiovascular mortality), three Cox proportional hazards regression models were performed. Model 1 included only covariates. Next, Model 2 included covariates included in Model 1 as well as depressive symptoms (PHQ-9 Ͻ5 ϭ 0, PHQ-9 Ն5 ϭ 1). Finally, Model 3 included medication nonadherence to assesse whether medication adherence attenuated the hypothesized relationship between depressive symptoms and mortality. All analyses were repeated, treating PHQ-9 scores continuously.
Results

Sample Characteristics
The sample included 308 patients with HF with an average age of 68.5 Ϯ 9.64 years. Complete participant characteristics stratified by depressive symptoms are presented in Table 1 .
Participants averaged 996.08 Ϯ 334.03 days of follow-up (median ϭ 1048). During follow-up, 51 deaths (16.8%) occurred. Forty-three percent of deaths (n ϭ 22) were classified as cardiovascular. Of the sample, 104 patients (34.3%) were classified as at least mildly depressed (PHQ-9 Ն 5). Of the depressed individuals, 22 (21.2%) experienced the primary outcome (i.e., mortality) by the end of follow-up. Eight participants classified as depressed died from a cardiovascular cause. This document is copyrighted by the American Psychological Association or one of its allied publishers.
Primary Analyses
Depressive symptoms and medication nonadherence. A hierarchical multiple linear regression analysis was performed to examine the relationship between depressive symptoms (PHQ-9 Ն5) and medication nonadherence. In the first block, the linear combination of demographic and clinical covariates explained 2.7% of the variability in medication nonadherence, F(3, 304) ϭ 2.81, p Ͻ .05. In the second block, the addition of depression significantly improved model fit, ⌬R 2 ϭ .03, ⌬F(1, 303) ϭ 10.56, p Ͻ .01. Depressive symptoms were positively related to medication nonadherence, (␤ ϭ .19, p Ͻ .01).
All-cause mortality. A series of Cox proportional hazards regression analyses were conducted to assess the relationships between depression, medication nonadherence, and all-cause mortality risk before and after adjustment for covariates. Univariate analysis indicated no relationship between depression and allcause mortality (HR ϭ 1.52; 95% CI [.88 -2.65]). Following adjustment for covariates, an association emerged between depression and all-cause mortality risk (HR ϭ 1.87; 95% CI [1.04 -3.37]) (see Figure 1) .
Next, medication nonadherence was added to the model. In the fully adjusted model, higher nonadherence remained associated with all-cause mortality (HR ϭ 1.01; 95% CI [1.004 -1.02]). Following adjustment for nonadherence, depression was no longer a significant predictor. Also, adjustment for nonadherence led to a 32.49% decrease in the age-adjusted log HR estimating the effect of depressive symptoms.
Cardiovascular mortality. A second series of Cox proportional hazards regression analyses were performed to examine the relationships between depressive symptoms, medication adherence, and cardiovascular mortality risk. Depression was not associated with cardiovascular mortality risk in a univariate or multivariate analysis.
In the final model, medication nonadherence was added to assess the relationship between nonadherence and cardiovascular mortality. Medication nonadherence was not associated with cardiovascular mortality. See Table 2 for a summary of univariate Cox proportional hazards models. Given the low number of cardiac deaths, this series of analyses were likely underpowered to detect an effect after adjusting for covariates. Multivariate analyses are presented in Tables 3 and 4 . This article is intended solely for the personal use of the individual user and is not to be disseminated broadly.
Secondary Analyses
A series of analyses were also conducted treating PHQ-9 scores as a continuous variable to assess the dose-response relationship between depressive symptoms and mortality.
Depressive symptoms and medication nonadherence. Hierarchical multiple linear regression tested the relationship between depressive symptoms and medication nonadherence. In the first block, the linear combination of covariates explained 2.7% of the variability in medication nonadherence, F(3, 304) ϭ 2.81, p Ͻ .05. In the second block, adding PHQ-9 scores accounted for an additional 3.0% of the variance in medication nonadherence and improved model fit, ⌬F(1, 303) ϭ 9.63, p Ͻ .01. Higher levels of depressive symptoms were associated with higher nonadherence, (␤ ϭ .19, p Ͻ .01).
All-cause mortality. Univariate analysis indicated no relationship between depression and all-cause mortality. Following covariate adjustment, higher depressive symptoms were related to increased all-cause mortality (HR ϭ 1.06; 95% CI [1.01-1.12]).
Multivariate analyses examining relationships among medication nonadherence and mortality were also performed. Medication nonadherence was associated with increased mortality risk after adjustment for covariates and depressive symptoms (HR ϭ 1.01; 95% CI [1.003-1.02]). When nonadherence was added to the model, depressive symptoms were no longer significantly related to mortality risk. This represents a 22.61% in the age-adjusted log HR estimating the effect of depressive symptoms when nonadherence was added to the model.
Depressive symptoms, medication nonadherence, and cardiovascular mortality. Finally, Cox proportional hazards models were conducted to examine relationships among depressive symptoms, medication adherence, and cardiovascular mortality. No univariate nor multivariate relationship emerged between depressive symptoms and cardiovascular mortality. A fully adjusted model including medication nonadherence showed no relationship between medication nonadherence and mortality risk. However, given the low number of cardiac deaths, this series of analyses were likely underpowered to detect an effect.
Discussion
Here we report that the presence of at least mild depressive symptoms was associated with lower adherence and increased all-cause and cardiovascular mortality risk in HF. Medication Note. NYHA ϭ New York Heart Association; PHQ-9 ϭ Patient Health Questionnaire-9. PHQ-9 (categorical): 0 ϭ not depressed; 1 ϭ depressed. Note. NYHA ϭ New York Heart Association; PHQ-9 ϭ Patient Health Questionnaire-9. a Given the low number of cardiac deaths, this series of analyses were likely underpowered to detect an effect after adjusting for covariates. This document is copyrighted by the American Psychological Association or one of its allied publishers.
nonadherence was also related to mortality risk; as medication nonadherence increased 1%, mortality risk increased by 1%, indicating that a 10% increase in medication nonadherence reflected a 12% increase in 2.7-year mortality risk. Medication nonadherence attenuated the relationship between depressive symptoms and allcause mortality. When treated as a continuous variable, depressive symptoms were again positively associated with all-cause, but not cardiovascular, mortality. A graded association between depression severity and all-cause mortality risk emerged. Each 1-point increase in depressive symptoms corresponded to nearly a 10% increase in all-cause mortality risk, which appeared to be partially accounted for by medication nonadherence. We believe that this is the first report on the contribution of objectively measured medication adherence to the relationship between depression and mortality in patients with HF. This finding adds to a large body of research demonstrating the association between increasing depression severity and poor prognosis in HF.
In line with hypotheses, depressive symptoms were positively associated with medication nonadherence. There are several potential explanations for this relationship. Motivation and fatigue associated with depression may impede adherence to treatment recommendations. An exploration of relationships among depression, anxiety, and fatigue in HF revealed that depression and anxiety were associated with different aspects of fatigue (Falk, Patel, Swedburg, & Ekman, 2009) . Individuals with anxiety displayed more mental fatigue (Falk et al., 2009) . Depression was linked to fatigue-related reductions in activity, motivation, and functioning (Falk et al., 2009 ). Falk et al. (2009) suggested that depression may interfere with activity because of decreased energy necessary to follow through with self-care activities. The directionality of these comorbid factors needs clarification.
Furthermore, negative thinking and poor coping prevalent in depression may contribute to nonadherence. HF patients with depression appear more likely to employ coping methods such as denial and disengagement as opposed to active coping, acceptance, and planning-related coping strategies (Allman, Berry, & Nasir, 2009; Klein, Turvey, & Pies, 2007) . This is unfortunate because problem-focused and emotion-focused (such as acceptance) coping strategies appear to be related to better self-care in HF (Li & Shun, 2016) . It is likely that individuals able to demonstrate flexibility when using emotion-or problem-focused strategies experience advantages regarding managing a chronic illness; for example, individuals may use problem-focused strategies to manage concrete barriers to disease management or emotion-focused strategies, such as acceptance or emotional support seeking, when negative mood may otherwise impact motivation for self-care. Depression may dampen such flexibility.
In addition to regimen-related factors, patient beliefs about their disease and the efficacy of treatment may also impact medication-taking behavior. For example, patients who view their disease as fatal with little hope for longevity or improvement may be less prone to adhere to medication protocols (Rashid, Edwards, Walter, & Mant, 2014) . In addition, beliefs more specifically related to the necessity or concerns related to side effects of medications likely impact adherence (Horne et al., 2013) , and depressive symptoms may also impact the balance of weighing potential necessity and advantages versus side effects and costs. Because depression is associated with negative thinking styles, including hopelessness and negative views of the future, depressed patients may also hold negative beliefs about the efficacy of their treatment regimens.
Both depression and poor medication adherence represent modifiable, prognostic risk factors. The relationship between depression and risk for poor prognosis in patients with HF is likely impacted by a number of physiological changes that occur in both CVD and depression as well as behavioral factors (Joynt, Whellan, & O'Connor, 2004; Kop, Synowski, & Gottlieb, 2011; Whooley et al., 2008; Zuluaga et al., 2010) . A number of behavioral factors, in addition to medication adherence, may also play a role. Although behaviors such as physical activity, diet, smoking, and medication taking represent different aspects of health and disease management, many of these Note. NYHA ϭ New York Heart Association; PHQ-9 ϭ Patient Health Questionnaire-9. a Given the low number of cardiac deaths, this series of analyses were likely underpowered to detect an effect after adjusting for covariates.
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factors covary. For example, medication nonadherence is often considered a marker of several unhealthy lifestyle behaviors associated with an increased risk of cardiac events and poor outcomes (Bonnet et al., 2005; Whooley, 2006; Simpson et al., 2006) . As such, it remains possible that medication nonadherence in the current study may serve as a proxy of poor engagement in other heath behaviors. Prior research exploring these mechanisms of action has suggested physical inactivity to be an important behavioral factor (Whooley et al., 2008; Zuluaga et al., 2010) . Whooley et al. (2008) demonstrated that physical inactivity was the largest behavioral factor impacting the relationship between depressive symptoms and risk of experiencing cardiac events, reducing the age-adjusted log HR by 31%. Self-reported medication nonadherence reduced the ageadjusted log HR by 5.3%. The current investigation, which incorporated objectively measured medication adherence, found a significant impact on the association between depressive symptoms and all-cause mortality.
Limitations
Limitations of the current study warrant mention. The mortality rate in the current study was lower than expected. Similar studies of HF with follow-up periods of 18 months (Coyne et al., 2011) and 32 months (Faller et al., 2007) reported mortality rates of 27.4%, and 26%, respectively. The low mortality rate may be attributed to recruitment of motivated, well-managed patients who are closely followed by their cardiologists. Nonetheless, the presence of at least mild symptoms of depression conferred a significant increase in mortality risk, with individuals reporting elevated depressive symptoms experiencing mortality at greater than twice the rate of individuals who did not report elevated symptoms. Similarly, Rutledge, Reis, Linke, Greenberg, and Mills (2006) reported approximately a 2-fold all-cause mortality risk for depressed individuals with HF.
Furthermore, many of the relationships that emerged when examining all-cause mortality were not evident for cardiovascular mortality. This may be a result of the low rate of cardiovascular deaths, leading to limited power to detect an effect. A prior meta-analysis suggested that increased cardiovascular mortality was associated with depressive symptomology in HF (Fan et al., 2014) . In an analysis of 48,117 HF patients identified through hospital records as receiving psychotropic treatment for depression prior to an HF diagnosis, Macchia et al. (2008) suggested that increased rates of 1-year all-cause mortality among patients previously treated for depression were largely caused by increased rates of vascular events (i.e., myocardial infarction, stroke, transischemic attack). Future studies may benefit from larger sample sizes and/or longer follow-up periods to detect relationships with cardiovascular mortality. The possibility remains that CVD contributed to some deaths that were recorded as noncardiac (e.g., falls), given that National Death Index-recorded causes of death were not adjudicated by obtaining individual death certificates or examining hospital records.
In addition, the direction of the relationship between depressive symptoms and medication adherence could not be established, given the current study design. Finally, history of depression was not assessed. It will be important for future research to explore whether recurrent depressive episodes or newly onset depression following development of CVD are differentially related to prognosis. Changes in depressive symptoms over time could not be investigated in the current study, but the persistence of depression may be differentially associated with mortality risk relative to single-episode or remitting symptoms of depression. Similarly, changes in medication adherence over time may contribute to changes in mortality risk.
Conclusions and Future Directions
Medication nonadherence contributes to the relationship between depression and all-cause mortality risk in individuals with HF. Future research is needed to explore how depression and medication adherence relate to other outcomes (e.g., cardiovascular mortality, cardiac events, hospitalization) in larger samples or in samples with longer follow-up. Health care providers should continue to screen patients for depressive symptoms and monitor changes in mood because even mild symptoms of depression can indicate a risk for poor medication adherence and prognosis. However, the evidence-base for treatment recommendations is sparse at this time. Cognitivebehavioral therapy reduces depression in HF and appeared to reduce hospitalizations, but it did not improve self-care assessed via self-report (Freedland, Carney, Rich, Steinmeyer, & Rubin, 2015) . With respect to antidepressants, neither sertraline nor escitalopram was effective for depression in HF (Angermann et al., 2016; O'Connor et al., 2010) . Perhaps interventions should address medication adherence directly, although a pilot clinical trial of medication reminding found no improvement in adherence from pillbox alarms or smartphone reminders (Goldstein et al., 2014) . Medication adherence interventions for patients with HF need further refinement and evidence of effectiveness. Obviously whether improvements in medication adherence would reduce the risks associated with depression symptoms is not known. Cardiac rehabilitation (CR) programs, which have become more available to HF patients in recent years, have been offering a promising setting to target mood, adherence, and other health behaviors such as physical activity. Mood improvement is commonly observed following CR, and many comprehensive CR programs offer opportunities for engagement with a psychologist and/or pharmacist in addition to monitored exercise. Nonetheless, increased awareness of the impact of depression on the quality and quantity of life in patients with HF will likely benefit patients, families, and providers by encouraging the identification of targets for intervention and need for support.
